SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Imclone systems (IMCL)
IMCL 0.1590.0%Oct 5 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: 5,17,37,5,101,... who wrote (91)5/4/1998 11:39:00 AM
From: Abel Vieira  Read Replies (1) of 2515
 
IMCL is similar to ENMD! Why is it not moving higher! Here is the news story.

Systems Incorporated (NASDAQ: IMCL) today announced the presentation
of data at the annual meeting of the American Association for Cancer
Research concerning the Company's lead cancer therapeutic, C225, an
epidermal growth factor receptor. New preclinical in vivo findings
demonstrated that C225 decreased tumor growth and increased survival
in animal models of human renal cell carcinoma. In other studies
evaluating mechanism of action, C225 was shown to inhibit angiogenesis
(the formation of blood vessels) associated with human transitional
cell carcinoma, a form of bladder cancer, through down regulation of
Vascular Endothelial Growth Factor expression.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News